A Chinese Real-world Study to Investigate the Management Pattern and Outcomes of Chronic Thromboembolic Pulmonary Hypertension (CHANGE Study)

What this Trial Is About

Researchers are conducting a multi-center, observational study in China to collect detailed information about patients with chronic thromboembolic pulmonary hypertension (CTEPH). The study aims to better understand the occurrence, management, and long-term outcomes of this condition by gathering data from 18 specialized centers. It focuses on how CTEPH is diagnosed and treated in real-world settings, supported by the China-Japan Friendship Hospital. The study observes patients receiving different treatments for CTEPH, including pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), or various pulmonary arterial hypertension (PAH)-specific medications such as endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. Treatment decisions are made by a multidisciplinary team based on each patient's disease characteristics and preferences. Participants are grouped according to the therapy they receive, and no experimental treatments or randomization are involved. Participants will be followed for three years, during which researchers will monitor key health indicators like mean pulmonary artery pressure, pulmonary vascular resistance, cardiac output, and walking distance. They will also assess biomarkers like BNP or NT-proBNP levels and functional status using WHO classification. Additional outcomes include transplantation rates and quality of life changes. Data collection includes routine clinical evaluations and long-term tracking of disease progression and treatment effects.

Change-a Multi-center Chronic Thromboembolic Pulmonary Hypertension （CTEPH） Database in China